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early phase of AMI in our study was based on ST segment
elevation and angiographically confirmed presence of a fresh
coronary occlusion. Identical criteria were applied for the control
group. Second, we specifically focused on VF and not on all fatal
arrhythmias as a whole. Severe bradyarrhythmias are reported up
to 30% in SCD (2). In studies on SCD the fatal arrhythmia is
seldom specified. In our study VF was confirmed by rhythm
recordings. So, studies on SCD are impossible to compare with our
study as long as VF, early phase of AMI and coronary anatomy are
not simultaneously specified.
The main finding of our study was that acute occlusion in the
left coronary artery is associated with greater risk for out-of-
hospital VF compared with the right coronary artery in the early
phase of AMI. This finding is not the result of differential
selection. We fully agree that the AMI patients in our study do not
represent all patients with AMI. To reach the group of “AMI with
VF,” patients had to survive VF. To explain our findings by
selection bias, as suggested by Mikkelsson, one has to assume that
patients with out-of-hospital VF and occlusion of left coronary
artery have a higher probability of being admitted than patients
with out-of-hospital VF and occlusion of right coronary artery. To
the best of our knowledge, there are no data suggestive of this
assumption.
The comments of Mikkelsson and our article raise another
important field of interest: What is the effect of site of occlusion on
life-threatening bradyarrhythmias in the early phase of AMI?
Therefore, studies on SCD that document bradyarrhythmias, early
phase of AMI and coronary anatomy would be very interesting.
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Underestimation of the
Valvulopathy Effect of Fenfluramine
In an effort to evaluate the relationship between the use of
fenfluramines as diet drugs and the prevalence of mitral valve and
aortic valve regurgitation, Burger et al. (1) compared measure-
ments from a study conducted for another purpose to those
described by Singh (2). Burger observed that the prevalence of
mitral valvulopathy in his study was comparable with the Framing-
ham study (1.3% vs. 1.6% from Framingham) and aortic regurgi-
tation (6.6% vs. 4.8% from the Framingham study). Burger
surmised that the valvulvar regurgitation seen in his patients may
not be due to fenfluramine but to age-related degenerative
changes. Schiller (3), in an accompanying editorial, seconds this
point of view stating (page 1161), “It would seem then that as
studies have become more scientifically rigorous, the role of
fen/phen in valve disease appears to be approaching the vanishing
point.” However, there are two important additional observations
concerning Burger’s methodology that undermine these conclu-
sions.
There were 591 patients in Burger’s study. Of these patients,
only 226 (38.2%) returned for an echocardiogram. The remaining
365 patients who were also exposed to the fenfluramines, for
unknown reasons, did not undergo echocardiography. Since only
three of the 226 patients who returned had mitral regurgitation,
and only 15 of the 226 patients had aortic regurgitation, the fate of
the remaining 365 patients is critical in a proper assessment. The
absence of the echocardiograms in over 60% of the cohort makes
this study especially vulnerable to selection bias.
A second concern involves Burger’s simple comparison between
regurgitation prevalence in his population and Framingham. The
difference in the mean ages between that of Burger’s cohort (mean
age 46.9, standard deviation 8.9) and that of the Framingham
population (mean age 55, standard deviation 10) suggests that a
coarse comparison of the crude prevalences from these two
populations is inappropriate and misleading. Fortunately a more
appropriate adjustment is available through an examination of
Singh’s data (4). Given both the mean age (standard deviation) and
the gender distribution provided by Burger one can, assuming the
normal distribution, approximate the distribution of age and
gender in the Burger study. From Singh (4) the prevalence of each
of mitral regurgitation and aortic regurgitation is available
(Table 1).
From Table 1 one can compute the expected prevalence in the
Burger cohort based on the gender and age-specific mitral and
aortic valve prevalence in the Framingham study. If the 10.2% of
patients whose ages are outside the 26 to 83 age range (based on
a normal distribution with mean age 46.9 and standard deviation
8.9) fall in the upper age range (greater than 83) and these patients
have the same prevalence of valvular regurgitation as those in the
70 to 83 age range, the computations reveal that the expected
prevalence for mitral regurgitation (Food and Drug Administra-
tion criteria) is 1.0% and for aortic regurgitation is 3.3%. This
conservative computation provides mitral and aortic prevalences
that are less than those observed by Burger. Based on these age-
and gender-adjusted prevalences, the prevalences seen by Burger et
al. are greater than would be expected from degenerative changes
alone.
These two observations substantially weaken the explanation
provided by Burger. Since Schiller chose to build his conclusions
on Burger’s results, this editorial’s foundation is now effectively
removed. The data collected by Burger, while representing an
incomplete assessment, support, rather than refute, the association
found between fenfluramine and cardiac valvulopathy.
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Both Dr. Moye´ and Dr. Annegers have been retained by counsel
as experts for the plaintiffs in ongoing fenfluramine litigation.
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REPLY
Phentermine and Fenfluramine (phen-fen) were popular medica-
tions for the treatment of obesity. After the Mayo clinic report (1),
numerous anecdotal reports and several small, nonrandomized
observational surveys (2) described significant, unsuspected cardiac
pathology in patients formerly on these drugs. Although the
methodology of these surveys differed, the prevalence of valvular
disease meeting the Food and Drug Administration case definition
for significant valvular regurgitation was similar in all five surveys
and ranged from 30 to 38% (overall: 32.8%). These findings
alarmed both the medical community and the general public.
There was a great concern that a “virtual epidemic” of valvular
disease was upon us.
In our study (3) only 18 subjects (8%) had significant valvular
regurgitation as defined by Food and Drug Administration criteria.
The most common finding was mild or greater aortic insufficiency
in 15 subjects and 3 subjects with moderate mitral regurgitation.
No subjects had severe regurgitation of any valve. The dose or
duration of medications did not appear to be significant.
Our study is just another piece of the puzzle; it is not the final
answer. Our data showed a much lower prevalence of valvular heart
disease. As stated in the article, our study has multiple limitations.
First, all subjects did not have an echocardiographic evaluation.
However, all patients were followed clinically. All patients were
asymptomatic; no new murmurs were found, and no subjects
underwent cardiac surgery. No significant clinical differences were
found between subjects who had echocardiograms performed and
those who did not. Our study could be biased to overestimate the
prevalence of valve disease because subjects who returned for an
echocardiogram may have been concerned about a heart problem,
while those who did not return were not.
Second, our study noted the inherent inaccuracies that exist in
differentiating relatively mild degrees of valvular regurgitation, that
is, trace versus mild aortic regurgitation (since most studies to date
have found mild aortic regurgitation to be the problem). The
differentiation of trace from mild degrees of valvular regurgitation
is subjective and problematic, especially when trace is considered
normal and mild is considered a “disease.” Furthermore, it is very
important to distinguish between a clinical diagnosis and an
echocardiographic finding.
Third, heart valves degenerate over time and become “leaky.” A
significant proportion of healthy men and women have detectable
valvular regurgitation by color Doppler. This is not a disease, and
these subjects will probably never develop a clinical syndrome.
These valvular abnormalities represent age-related degenerative
changes. The Food and Drug Administration’s criteria for valvular
regurgitation are too narrow and arbitrary, and the case definition
for pathologic regurgitation needs to be modified and age-specific.
Fourth, our study did not have a control group. Our informal
comparison to the Framingham study (4) was done only to assist
the reader’s understanding of the prevalence of valvular regurgita-
tion in phen-fen users and in the normal population. After
reproducing Doctors Moye and Annegers’ analysis, we then used
our study population to estimate the expected prevalence of valve
disease based on the published Framingham data. We found the
prevalence ratio for mitral and aortic regurgitation to be 0.67 and
1.29, respectively. However, we found an error in their calculation
of the total expected prevalence, which should have been a
weighted average expected prevalence. With this correction, the
prevalence ratio for mitral and aortic regurgitation becomes 1.34
and 3.13, respectively (Table 1).
Finally, the true risk of diet drugs to cause pathologic valvular
regurgitation is still unknown. Initial reports suggested a possible
epidemic of valve disease with the prevalence up to 38% of users.
Our study questions the degree to which phen-fen therapy
contributes to valvular regurgitation. Long-term, prospective, ran-
Table 1. Adjusted Cardiac Valvulopathy Prevalences
Proportion in Patients in Burger’s Population
Expected Prevalence
Mitral Regurgitation Aortic Regurgitation
Age Men Women Total Men Women Men Women
26–39 0.034 0.144 0.178 0 0 0 0
40–49 0.071 0.303 0.374 0.003 0.009 0.017 0.007
50–59 0.053 0.224 0.277 0.016 0.01 0.042 0.021
60–69 0.012 0.052 0.064 0.024 0.023 0.127 0.068
70–83 0.001 0.004 0.005 0.112 0 0.144 0.169
.83 0.019 0.083 0.102 0.112 0 0.144 0.169
Expected Prevalence 0.004 0.006 0.008 0.025
Total Expected Prevalence 0.010 0.033
Observed Prevalence 0.013 0.066
Prevalence Ratio 1.33 2.01
Table 1 reports the contribution of each gender-age category from Burger’s population to the expected prevalence. The expected
prevalence for each valve is computed and compared with the observed prevalence in Burger’s population.
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